報價延遲最少15分鐘:2025/06/06 01:09 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.61 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.75/-3.22
|
|
企業價值
1.01B
|
| 資產負債 |
|
每股賬面淨值
5.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/06 01:09 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two ormore lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |